30 Search Results

q=Myeloma

Search Again


Alice Berger , PhD

Email: ahberger@fredhutch.org

Phone: (206) 667-6281

The goal of the Berger laboratory is to enable precision medicine by systematically uncovering the molecular alterations in cancer, determining the function of these variant alleles, and understanding how these alleles modulate response to targeted or immune-based therapies. Although many of the genes involved in cancer have now been identified, a major challenge is discovering which specific alleles of these genes are involved and how these alleles modulate therapeutic response. We combine functional genomics, computational biology, biochemistry, and genetics to understand the mechanism of somatic cancer variants. Our goal is to identify drug targets and biomarkers and to translate this knowledge into clinical benefit for patients.

View Bio

Aude Chapuis , MD

Email: achapuis@fredhutch.org

Phone: (206) 667-4369

Dr. Chapuis’ translational research laboratory is developing novel ways to modulate the immune system to target cancer. Her research is especially focused on 1) understanding the factors associated with successful “adoptive” transfer of immune T cells and improving the therapeutic efficacy of both natural (native) and gene-modified T cells targeting viral and tumor antigens, and 2) developing methods that improve the survival, proliferation and anti-tumor activity of infused T cells so as to better eliminate tumor targets. These advances are in turn used to 3) develop clinical strategies to optimally activate therapeutic T cells to specifically eliminate cancer in patients, without the noxious side effects of chemotherapy.

View Bio

Thomas Chauncey , MD

Email: tchaunce@u.washington.edu

Dr. Chauncey is a medical oncologist who treats leukemia with bone marrow transplantation.

View Bio

Eric Chow , MD, MPH

Email: ericchow@uw.edu

Phone: (206) 667-7724

Dr. Chow studies late effects related to pediatric cancer and blood disorder therapy.

View Bio

Bruce Clurman , MD, PhD

Email: bclurman@fredhutch.org

Phone: (206) 667-4524

Dr. Clurman's studies the pathways that regulate cell growth and division in order to understand the molecular mechanisms that drive tumorigenesis and to develop new cancer therapies. His research focuses on two general areas: cellular regulation by the ubiquitin-proteasome system, and control of cell division by cyclin-dependent kinases (CDKs).His clinical practice is focused on hematopoietic stem cell transplantation.

View Bio

Andrew Cowan , MD

Email: ajcowan@fredhutch.org

Phone: (206) 667-7348

Dr. Cowan specializes in indolent lymphomas, multiple myeloma, and AL amyloidosis and is involved in clinical trials in lymphomas.

View Bio

David Fredricks , MD

Email: dfredric@fredhutch.org

Phone: (206) 667-1935

Dr. Fredricks's lab has identified several fastidious bacterial species that are useful markers of BV and are associated with adverse health outcomes. They are using novel cultivation methods to propagate some of these bacteria in the lab, and study how indigenous microbes interact with each other and the human host. He is currently looking for collaboration in molecular biology, microbiology, immunology, and cell biology. He is also looking for collaborators to focus on clinical epidemiology by studying microbial ecology in different human hosts.

View Bio

Ted Gooley , PhD

Email: tgooley@fredhutch.org

Phone: (206) 667-6533

Dr. Gooley's research is focused on clinical trials and methods of data analysis in stem cell transplantation.

View Bio

Damian Green , MD

Email: dgreen@fredhutch.org

Phone: (206) 667-5398

Dr. Green’s laboratory and clinical research is focused on developing new immunotherapeutic approaches to treat and ultimately eradicate multiple myeloma and lymphoma.

View Bio

Geoff Hill , MD, FRACP, FRCPA

Email: grhill@fredhutch.org

Phone: (206) 667-3324

Dr. Hill is a physician-scientist who specializes in blood stem cell transplantation and is one of the top authorities on graft-vs.-host disease (GVHD). In particular, he focuses on the immunological mechanisms initiating both acute and chronic forms of GVHD. His lab research is demonstrating how cytokines direct immune cells that play critical roles in transplant outcomes. He is also developing methods to integrate transplantation with other forms of cancer immunotherapy like T-cell therapy.

View Bio

Leona Holmberg , MD, PhD

Email: lholmber@fredhutch.org

Phone: (206) 667-6447

Dr. Holmberg is an immunologist and physician who specializes in bone marrow and blood stem cell transplantation and immunotherapy. Her research focuses on trying to augment the immune system after an autologous transplant. To test ways of reducing relapse, she is engaged in numerous clinical trials of drug combinations, including the use of immunotherapy drugs and vaccines, to bolster a patient’s post-transplant immune function.

View Bio

Billanna Hwang , MPH, DHSc

Email: bhwang@uw.edu

Dr. Hwang’s research focuses include development of immunotherapies in lung and VCA transplants, tolerance and acute/chronic rejection immunology (Tregs), pathophysiology of GVHD, NSCLC, and exosome biology (therapies, biomarker). Most recently, her group has expanded using cell and exosome based immunotherapies in Cystic Fibrosis and role of bioengineered materials to promote regeneration through exo-mechanisms.

View Bio

Teresa Hyun , MD, PhD

Email: thyun@fredhutch.org

Phone: (206) 606-1345

Dr. Hyun is a pathologist who works in hematopathology and bone marrow transplant pathology. Her clinical work involves evaluation of hematolymphoid malignancies which may require treatment with bone marrow/stem cell transplantation and monitoring of post-transplant conditions such as graft-versus-host disease as part of the clinical team treating patients at SCCA.

View Bio

Elizabeth Krakow , MD

Email: efkrakow@fredhutch.org

Phone: (206) 667-3410

Dr. Krakow is interested in using HLA-mismatched non-engrafting cell therapy to treat cancer. The goal is to avoid graft-versus-host disease and long-term immunosuppression, but still harness transient benefits of direct alloreactivity while restoring the recipient (or original donor) immune system’s cancer surveillance and eradication mechanisms. She also studies how to deliver personalized recommendations for sequences of chemo/immunotherapies.

View Bio

Yawen Li , PhD

Email: liyw@uw.edu

Phone: (206) 616-8518

Dr. Li is interested in therapeutic and diagnostic radiopharmaceuticals, astatine labeling reagents for small molecule labeling, and developing chemical methods for separation of high specific activity medical radionuclides.

View Bio

Edward Libby , MD

Email: elibby@seattlecca.org

Phone: (206) 288-1453

Dr. Libby's research is focused on finding new and improved treatments for patients with multiple myeloma, Waldenstrom's macroglobulinemia, amyloidosis, and lymphoma.

View Bio

Michael Linenberger , MD

Dr. Linenberger in interested in the institutional practices, policies and procedures to ensure the safe procurement of blood marrow cells from healthy donors and from patients with a variety of diseases.

View Bio

David Maloney , MD, PhD

Email: dmaloney@fredhutch.org

Phone: (206) 667-5616

Dr. Maloney applies the latest research on new treatments when treating his patients for chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, and multiple myeloma.

View Bio

Daniel Martin , MD

Email: dmartin@seattlecca.org

Phone: (206) 288-1284

Dr. Martin is a hematologist who treats lymphomas, chronic lymphocytic leukemia, multiple myeloma, and non-malignant blood disorders.

View Bio

Paul Martin , MD

Email: pmartin@fredhutch.org

Phone: (206) 667-4798

Dr. Martin is a medical oncologist who uses marrow or blood cell transplantation to treat leukemia, myelodysplastic syndromes, lymphoma, myeloma and other diseases. His research focuses on the treatment and prevention of acute and chronic graft-versus-host disease, as well as the management of late complications after marrow or blood cell transplantation

View Bio